Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Acotec Scientific Holdings Limited ( (HK:6669) ) is now available.
Acotec Scientific Holdings Limited announced that all resolutions proposed at its extraordinary general meeting held in Beijing on 31 December 2025 were duly passed by shareholders through poll voting. Independent shareholders representing about 61.2% of the eligible free-float participated, with the key ordinary resolution approving, ratifying and confirming the 2026 Master Collaboration Agreement with controlling shareholder BSG, including the framework for non-exempt continuing connected transactions and related annual caps. The strong approval level, with over 99% of votes cast in favour of the main resolution and the controlling shareholder abstaining as required, provides formal shareholder backing for the company’s planned collaboration framework with BSG, paving the way for continued operational cooperation under clearer governance and compliance with Hong Kong listing rules.
The most recent analyst rating on (HK:6669) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Acotec Scientific Holdings Limited stock, see the HK:6669 Stock Forecast page.
More about Acotec Scientific Holdings Limited
Acotec Scientific Holdings Limited is a medical technology company listed in Hong Kong that develops and commercialises interventional medical devices, with a focus on minimally invasive therapies for cardiovascular and other vascular diseases in the Chinese and broader international markets.
Average Trading Volume: 443,798
Technical Sentiment Signal: Buy
Current Market Cap: HK$4.45B
Learn more about 6669 stock on TipRanks’ Stock Analysis page.